NCT05388617 is a NA clinical trial of Brera in Muscle Stimulation, sponsored by Cynosure, Inc..

Who is sponsoring NCT05388617?

NCT05388617 is sponsored by Cynosure, Inc..

What drugs are being tested in NCT05388617?

Interventions in NCT05388617: Brera.

What condition does NCT05388617 study?

NCT05388617 studies Muscle Stimulation, Abdominal Fat.

Is NCT05388617 still recruiting?

NCT05388617 is currently terminated. Last updated 29 November 2023.

Are results published for NCT05388617?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-11-29 · How we verify

NCT05388617

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study To Assess Radiofrequency Diathermocontraction Device For Muscle Stimulation And The Treatment Of Abdominal Fat

Terminated NA Results posted Last updated 29 November 2023

What this trial tests

NA trial testing Brera in Muscle Stimulation in 16 participants. Terminated before completion.

Timeline

10 May 2022

Primary endpoint
24 August 2022

24 August 2022

Quick facts

Lead sponsor	Cynosure, Inc.
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	10 May 2022
Primary completion	24 August 2022
Estimated completion	24 August 2022
Sites	1 location across United States

Drugs / interventions tested

Brera

Conditions studied

Muscle Stimulation — all drugs for Muscle Stimulation →
Abdominal Fat — all drugs for Abdominal Fat →

Sponsor

Cynosure, Inc. — full company profile →

Who can join

18 and older, any sex, with Muscle Stimulation or Abdominal Fat. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Subjects Satisfied Primary · 30 days follow up.

The number of subjects satisfied with their treatment will be reported.

Group	Value	95% CI
Group A	10

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse events were captured throughout subject participation in the study, approximately 30 days.. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Group A

Serious: 0/16 (0%)

Deaths: 0/16

Group B

Serious: 0

Deaths: 0

Other adverse events (4 terms — click to expand)

Reaction	System	Group A	Group B
Pain/Tenderness	Skin and subcutaneous tissue disorders	—	—
Cramping	Skin and subcutaneous tissue disorders	—	—
Erythema	Skin and subcutaneous tissue disorders	—	—
Muscle Twitching	Skin and subcutaneous tissue disorders	—	—

Data from ClinicalTrials.gov NCT05388617 adverse events section.

Sponsor's own description

The intended use of the device in this study to assess the safety and efficacy of the adhesive electrodes for muscle stimulation and the treatment of abdominal fat on the abdomen and/or flanks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Cynosure, Inc. trials

Trials by the same sponsor.

NCT05847530 — Pilot Evaluation of the Cynosure Potenza™ System for Treatment of Cosmetic Dermatologic Skin Conditions · NA · completed
NCT06023303 — Prospective Clinical Study to Assess Safety and to Collect Data on Radiofrequency Microneedling Device(s) For the Purpos · NA · completed
NCT05590039 — Study To Evaluate The Safety And Efficacy Of The MyEllevate® Procedure · NA · completed
NCT05388604 — Clinical Study To Evaluate Paired Treatment With An Alexandrite Laser And Radiofrequency Microneedling For Facial Aging · NA · completed
NCT05102617 — Post Market Usability Evaluation Of The PicoSure Pro Device · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05388617 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cynosure, Inc.
Last refreshed: 29 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05388617.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing